SCHEMBL95209

SCHEMBL95209

[CH2]c1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.76
PTGS1 P23219 3/20 0.74
P2RX1 P51575 1/20 0.71
MAPT P10636 1/20 0.68
KCNK3 O14649 2/20 0.68
RAB9A P51151 2/20 0.64
MEN1 O00255 1/20 0.64
HTT P42858 1/20 0.64
KMT2A Q03164 1/20 0.64
KCNK9 Q9NPC2 1/20 0.63
KCNQ3 O43525 2/20 0.62
KCNQ2 O43526 2/20 0.62
KCNE1 P15382 2/20 0.62
KCNQ1 P51787 2/20 0.62
KCNQ5 Q9NR82 1/20 0.61
POLB P06746 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61
NPC1 O15118 1/20 0.60
RHOC P08134 1/20 0.60
RHOA P61586 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28668959 0.87 LMNA (0.83) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL30739967 0.87 LMNA (0.78) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL30739929 0.86 LMNA (1.00) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL4517587 0.86 LMNA (1.00) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL8363755 0.85 MEN1 (0.77) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL25648987 0.85 LMNA (0.76) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL96330 0.85 MAPT (0.73) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL3237785 0.85 LMNA (0.76) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL3454009 0.85 PTGS1 (1.00) LMNAPTGS1P2RX1MAPTKCNK3
SCHEMBL5131380 0.85 RHOC (0.80) LMNAPTGS1P2RX1MAPTKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB LMNA 3740/4885PTGS1 32/4885P2RX1 4403/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 LMNA 4860/4885PTGS1 192/4885P2RX1 3260/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 LMNA 4860/4885PTGS1 192/4885P2RX1 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.